{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:57:40Z","timestamp":1791493060120,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011665","name":"Deanship of Scientific Research, King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004054","name":"King Abdulaziz University","doi-asserted-by":"publisher","award":["FP-050-43"],"award-info":[{"award-number":["FP-050-43"]}],"id":[{"id":"10.13039\/501100004054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.drudis.2022.06.005","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T11:28:27Z","timestamp":1655551707000},"page":"103305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Emerging therapeutic developments in neurodegenerative diseases: A clinical investigation"],"prefix":"10.1016","volume":"27","author":[{"given":"Dhiraj","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam","family":"Md Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar L.","family":"Bilgrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md","family":"Imtaiyaz Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.06.005_b0005","unstructured":"United Nations. World Population Prospects 2019. https:\/\/population.un.org\/wpp\/ Published 2019. Accessed April 13, 2022."},{"key":"10.1016\/j.drudis.2022.06.005_b0010","doi-asserted-by":"crossref","first-page":"101078","DOI":"10.1016\/j.arr.2020.101078","article-title":"Ubiquitin biology in neurodegenerative disorders: from impairment to therapeutic strategies","volume":"61","author":"Kumar","year":"2020","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.drudis.2022.06.005_b0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer's disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.drudis.2022.06.005_b0020","doi-asserted-by":"crossref","first-page":"787303","DOI":"10.3389\/fphar.2021.787303","article-title":"Topical insights into the post-approval controversies of aducanumab","volume":"12","author":"Kumar","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2022.06.005_b0025","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbrc.2021.11.040","article-title":"Neurodegenerative brain models vs. cell replacement or restoration therapy: a review on promises and pitfalls","volume":"585","author":"Kumar","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2022.06.005_b0030","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1242\/dev.143529","article-title":"Embryoids, organoids and gastruloids: new approaches to understanding embryogenesis","volume":"144","author":"Simunovic","year":"2017","journal-title":"Development"},{"key":"10.1016\/j.drudis.2022.06.005_b0035","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fnins.2019.00351","article-title":"Robust generation of person-specific, synchronously active neuronal networks using purely isogenic human iPSC-3D neural aggregate cultures","volume":"13","author":"Izsak","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1016\/j.drudis.2022.06.005_b0040","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nbt.3906","article-title":"Guided self-organization and cortical plate formation in human brain organoids","volume":"35","author":"Lancaster","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2022.06.005_b0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41467-020-20440-5","article-title":"A logical network-based drug-screening platform for Alzheimer's disease representing pathological features of human brain organoids","volume":"12","author":"Park","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2022.06.005_b0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13024-018-0258-4","article-title":"2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling","volume":"13","author":"Centeno","year":"2018","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.drudis.2022.06.005_b0055","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nbt.4127","article-title":"An in vivo model of functional and vascularized human brain organoids","volume":"36","author":"Mansour","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2022.06.005_b0060","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.neuron.2019.07.002","article-title":"Development of a chimeric model to study and manipulate human microglia in vivo","volume":"103","author":"Hasselmann","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2022.06.005_b0065","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1038\/540S49a","article-title":"Regenerative medicine","volume":"540","author":"Brody","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.06.005_b0070","first-page":"95","article-title":"Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase 1 clinical trial","volume":"1","author":"Kim","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.drudis.2022.06.005_b0075","unstructured":"Melamed D. $70 million raised for neuron replacement therapy techniques to treat Parkinson's. https:\/\/parkinsonsnewstoday.com\/2020\/04\/09\/70-million-raised-for-neuron-replacement-therapy-techniques-to-treat-parkinsons\/. Published April 9, 2020. Accessed April 13, 2022."},{"key":"10.1016\/j.drudis.2022.06.005_b0080","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13287-020-02126-3","article-title":"Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease","volume":"12","author":"Sumien","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.drudis.2022.06.005_b0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nprot.2016.008","article-title":"Isolation of ubiquitinated substrates by tandem affinity purification of E3 ligase-polyubiquitin-binding domain fusions (ligase traps)","volume":"11","author":"Mark","year":"2016","journal-title":"Nat Protoc"},{"key":"10.1016\/j.drudis.2022.06.005_b0090","doi-asserted-by":"crossref","first-page":"e46398","DOI":"10.1371\/journal.pone.0046398","article-title":"MultiDsk: a ubiquitin-specific affinity resin","volume":"7","author":"Wilson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2022.06.005_b0095","doi-asserted-by":"crossref","first-page":"180036","DOI":"10.1038\/sdata.2018.36","article-title":"Global quantitative analysis of the human brain proteome in Alzheimer's and Parkinson's disease","volume":"5","author":"Ping","year":"2018","journal-title":"Sci Data"},{"key":"10.1016\/j.drudis.2022.06.005_b0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bbrc.2021.10.073","article-title":"Ultra-sensitive techniques for detecting neurological biomarkers: prospects for early diagnosis","volume":"584","author":"Kumar","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2022.06.005_b0105","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1074\/mcp.O115.051839","article-title":"Enhanced purification of ubiquitinated proteins by engineered tandem hybrid ubiquitin-binding domains (ThUBDs)","volume":"15","author":"Gao","year":"2016","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.drudis.2022.06.005_b0110","first-page":"S465.7","article-title":"Proteomic analysis of the poly-ubiquitin profiles in Alzheimer's disease","volume":"33","author":"Zhang","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.drudis.2022.06.005_b0115","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s00018-014-1781-2","article-title":"Parkin-mediated K63-polyubiquitination targets ubiquitin C-terminal hydrolase L1 for degradation by the autophagy-lysosome system","volume":"72","author":"McKeon","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.drudis.2022.06.005_b0120","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1042\/BCJ20200937","article-title":"Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms","volume":"478","author":"Malik","year":"2021","journal-title":"Biochem J"},{"key":"10.1016\/j.drudis.2022.06.005_b0125","doi-asserted-by":"crossref","first-page":"101616","DOI":"10.1016\/j.arr.2022.101616","article-title":"Targeted protein degraders march towards the clinic for neurodegenerative diseases","volume":"78","author":"Kumar","year":"2022","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.drudis.2022.06.005_b0130","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2022.06.005_b0135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ddtec.2018.12.002","article-title":"SNIPERs-hijacking IAP activity to induce protein degradation","volume":"31","author":"Naito","year":"2019","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.drudis.2022.06.005_b0140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cyto.2014.07.104","article-title":"Trafficking and expression analysis of transferrin receptor-2 protein: a protein causes hemochromatosis type-3","volume":"70","author":"Khan","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/j.drudis.2022.06.005_b0145","series-title":"Alzheimer\u2019s Disease: Drug Discovery","article-title":"Tau protein-targeted therapies in Alzheimer's disease: current state and future perspectives","author":"Pluta","year":"2020"},{"key":"10.1016\/j.drudis.2022.06.005_b0150","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3233\/JAD-200134","article-title":"Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer's disease treated with escalating doses for up to 133 weeks","volume":"76","author":"Guthrie","year":"2020","journal-title":"J Alzheimer's Dis"},{"key":"10.1016\/j.drudis.2022.06.005_b0155","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.3390\/ijms22126355","article-title":"Neurotoxic soluble amyloid oligomers drive Alzheimer's pathogenesis and represent a clinically validated target for slowing disease progression","volume":"22","author":"Tolar","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2022.06.005_b0160","doi-asserted-by":"crossref","first-page":"e20200785","DOI":"10.1084\/jem.20200785","article-title":"Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model","volume":"217","author":"Wang","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2022.06.005_b0165","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/life11070607","article-title":"Chemical-mediated targeted protein degradation in neurodegenerative diseases","volume":"11","author":"Hyun","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.drudis.2022.06.005_b0170","doi-asserted-by":"crossref","first-page":"40362","DOI":"10.1039\/C7RA05347A","article-title":"Hydrophobic tagging-mediated degradation of Alzheimer's disease related Tau","volume":"7","author":"Gao","year":"2017","journal-title":"RSC Adv"},{"key":"10.1016\/j.drudis.2022.06.005_b0175","article-title":"Discovery of a molecular glue that enhances UPRmt to restore proteostasis via TRKA-GRB2-EVI1-CRLS1 axis","author":"Qi","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2022.06.005_b0180","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1038\/s41467-020-18871-1","article-title":"Health and disease markers correlate with gut microbiome composition across thousands of people","volume":"11","author":"Manor","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2022.06.005_b0185","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fncel.2019.00402","article-title":"In vitro characterization of gut microbiota-derived bacterial strains with neuroprotective properties","volume":"13","author":"Ahmed","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.drudis.2022.06.005_b0190","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3390\/genes12071006","article-title":"The genetics of Parkinson's disease and implications for clinical practice","volume":"12","author":"Day","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.drudis.2022.06.005_b0195","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1093\/nar\/gkz063","article-title":"Queuine links translational control in eukaryotes to a micronutrient from bacteria","volume":"47","author":"M\u00fcller","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2022.06.005_b0200","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1038\/s41380-019-0425-1","article-title":"Mid-life microbiota crises: middle age is associated with pervasive neuroimmune alterations that are reversed by targeting the gut microbiome","volume":"25","author":"Boehme","year":"2020","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.drudis.2022.06.005_b0205","doi-asserted-by":"crossref","first-page":"8538","DOI":"10.1007\/s12035-018-1003-2","article-title":"Kynurenic acid restores Nrf2 levels and prevents quinolinic acid-induced toxicity in rat striatal slices","volume":"55","author":"Ferreira","year":"2018","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.drudis.2022.06.005_b0210","article-title":"Therapeutic integrity of microbiome-based medicines in neurodegenerative disorders","author":"Kumar","year":"2022","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.drudis.2022.06.005_b0215","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.apsb.2020.01.015","article-title":"Gene therapy for neurodegenerative disorders: advances, insights and prospects","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2022.06.005_b0220","doi-asserted-by":"crossref","first-page":"19946","DOI":"10.1038\/srep19946","article-title":"Recombinant pre-miR-29b for Alzheime\u0155s disease therapeutics","volume":"6","author":"Pereira","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2022.06.005_b0225","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/17512433.2019.1567326","article-title":"Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"12","author":"Yang","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.drudis.2022.06.005_b0230","doi-asserted-by":"crossref","DOI":"10.1177\/1179573520907397","article-title":"Current and future treatments in Alzheimer disease: an update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J Cent Nerv Syst Dis"},{"key":"10.1016\/j.drudis.2022.06.005_b0235","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41587-020-0452-0","article-title":"Huntington's antisense drug marches into clinic","volume":"38","author":"Sheridan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2022.06.005_b0240","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2174\/1389203722666210615125852","article-title":"A mini-review on the effectiveness of peptoids as therapeutic interventions against neurodegenerative diseases","volume":"22","author":"Paul","year":"2021","journal-title":"Curr Protein Pept Sci"},{"key":"10.1016\/j.drudis.2022.06.005_b0245","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13195-015-0119-0","article-title":"A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease","volume":"7","author":"Nygaard","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.drudis.2022.06.005_b0250","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41398-019-0555-x","article-title":"Drug repurposing for Alzheimer's disease based on transcriptional profiling of human iPSC-derived cortical neurons","volume":"9","author":"Williams","year":"2019","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.drudis.2022.06.005_b0255","doi-asserted-by":"crossref","first-page":"e038911","DOI":"10.1136\/bmjopen-2020-038911","article-title":"Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial. The 'UP' study","volume":"10","author":"Payne","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.drudis.2022.06.005_b0260","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.drudis.2022.06.005_b0265","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3233\/JAD-190862","article-title":"NP03, a microdose lithium formulation, blunts early amyloid post-plaque neuropathology in McGill-R-Thy1-APP Alzheimer-like transgenic rats","volume":"73","author":"Wilson","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.drudis.2022.06.005_b0270","first-page":"330","article-title":"The price of progress: funding and financing Alzheimer's disease drug development","volume":"4","author":"Cummings","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.drudis.2022.06.005_b0275","first-page":"e12050","article-title":"Alzheimer's disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.drudis.2022.06.005_b0280","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12929-019-0609-7","article-title":"Clinical trials of new drugs for Alzheimer disease","volume":"27","author":"Huang","year":"2020","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.drudis.2022.06.005_b0285","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.neuron.2018.07.028","article-title":"A cortical pathogenic theory of Parkinson's disease","volume":"99","author":"Foffani","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2022.06.005_b0290","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41582-019-0155-7","article-title":"Emerging therapies in Parkinson disease\u2014repurposed drugs and new approaches","volume":"15","author":"Elkouzi","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.drudis.2022.06.005_b0295","first-page":"403039","article-title":"Dopamine receptors and Parkinson's disease","volume":"2011","author":"Hisahara","year":"2011","journal-title":"Int J Med Chem"},{"key":"10.1016\/j.drudis.2022.06.005_b0300","doi-asserted-by":"crossref","first-page":"222","DOI":"10.20517\/2347-8659.2020.58","article-title":"A review on Parkinson's disease treatment","volume":"8","author":"Lee","year":"2021","journal-title":"Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.drudis.2022.06.005_b0305","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40035-019-0180-x","article-title":"Replacing what's lost: a new era of stem cell therapy for Parkinson's disease","volume":"9","author":"Fan","year":"2020","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.drudis.2022.06.005_b0310","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1038\/d41586-021-02622-3","article-title":"The promise and potential of stem cells in Parkinson's disease","volume":"597","author":"Gravitz","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.06.005_b0315","doi-asserted-by":"crossref","first-page":"104712","DOI":"10.1016\/j.nbd.2019.104712","article-title":"Characterization of novel conformation-selective \u03b1-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease","volume":"136","author":"Henderson","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.drudis.2022.06.005_b0320","doi-asserted-by":"crossref","first-page":"597451","DOI":"10.3389\/fneur.2020.597451","article-title":"Deep brain stimulation initiative: toward innovative technology, new disease indications, and approaches to current and future clinical challenges in neuromodulation therapy","volume":"11","author":"Sui","year":"2021","journal-title":"Front Neurol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622002756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622002756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:02:24Z","timestamp":1761224544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644622002756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1359644622002756"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.06.005","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapeutic developments in neurodegenerative diseases: A clinical investigation","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103305"}}